论文部分内容阅读
目的:分析阿奇霉素对肺炎支原体肺炎(MPP)患儿IgA、IgG、IgM水平以及T淋巴细胞亚群(TLS)的影响。方法:选取MPP的86例患儿为研究对象。以数字法随机分成观察组(43例)和对照组(43例)。对照组以红霉素治疗,观察组则以阿奇霉素治疗。对比两组治疗前后免疫球蛋白情况以及TLS情况。结果:治疗后观察组患儿血清IgG与IgM水平分别为(10.37±2.38)g/L与(1.74±0.22)g/L,显著低于治疗前的(12.60±3.45)g/L与(1.99±0.34)g/L,差异均有统计学意义(P<0.05);治疗后观察组患儿血清IgG与IgM水平均显著低于对照组(P<0.05)。治疗后观察组和对照组IgA水平分别为(0.91±0.33)g/L与(0.92±0.23)g/L,与治疗前的(0.93±0.47)g/L与(0.94±0.52)g/L相比,差异均无统计学意义(P>0.05)。观察组治疗后CD4+水平和CD4+/CD8+比值分别为(46.38±5.07)与(1.45±0.25),显著高于治疗前的41.77±5.34与1.21±0.45,以及对照组治疗后的44.12±5.18与1.34±0.23,差异均有统计学意义(P<0.05)。观察组治疗后CD8+水平为30.12±4.13,显著低于治疗前的34.67±6.04,以及对照组治疗后的32.10±4.56,差异均有统计学意义(P<0.05)。结论:阿奇霉素治疗小儿MMP可明显改善患儿免疫球蛋白水平,优化TLS情况,疗效显著,值得临床推荐。
Objective: To analyze the effect of azithromycin on IgA, IgG and IgM levels and T lymphocyte subsets (TLS) in children with Mycoplasma pneumoniae (MPP). Methods: Eighty-six children with MPP were selected as study subjects. The patients were randomly divided into observation group (43 cases) and control group (43 cases). The control group was treated with erythromycin and the observation group was treated with azithromycin. Before and after treatment compared immunoglobulin situation and TLS situation. Results: The levels of IgG and IgM in the observation group were (10.37 ± 2.38) g / L and (1.74 ± 0.22) g / L, respectively, which were significantly lower than those before treatment (12.60 ± 3.45 g / L and 1.99 ± 0.34) g / L, the differences were statistically significant (P <0.05). After treatment, serum IgG and IgM levels in the observation group were significantly lower than those in the control group (P <0.05). The levels of IgA in observation group and control group after treatment were (0.91 ± 0.33) g / L and (0.92 ± 0.23) g / L respectively, which were significantly higher than those before treatment (0.93 ± 0.47 g / L and 0.94 ± 0.52 g / L Compared with no significant difference (P> 0.05). The levels of CD4 + and CD4 + / CD8 + in the observation group after treatment were (46.38 ± 5.07) and (1.45 ± 0.25), respectively, significantly higher than those of 41.77 ± 5.34 and 1.21 ± 0.45 before treatment and 44.12 ± 5.18 and 1.34 ± 0.23, the differences were statistically significant (P <0.05). The level of CD8 + in the observation group after treatment was 30.12 ± 4.13, significantly lower than 34.67 ± 6.04 before treatment and 32.10 ± 4.56 after treatment in the control group (P <0.05). Conclusion: Azithromycin treatment of infants with MMP can significantly improve the immunoglobulin levels in children, to optimize the TLS situation, the effect is significant, it is clinically recommended.